Immuron (IMRN) Receivables - Other (2016 - 2025)

Immuron (IMRN) posted quarterly Receivables - Other of $23688.0 for Q3 2025, up 56.14% quarter-over-quarter from $15170.6 in Q2 2025.

Immuron (IMRN) Receivables - Other (2016 - 2025) Analysis & Trends

Immuron's Receivables - Other history runs 5 years deep, the most recent figure standing at $23688.0 for Q3 2025.

In Q3 2025, Receivables - Other changed N/A year-over-year to $23688.0; the TTM figure through Sep 2025 stood at $23688.0 (changed N/A YoY), while the FY2025 annual figure was $23688.0, changed N/A from the prior year.
Receivables - Other for Q3 2025 stood at $23688.0, up from $15170.6 in the prior quarter.
The five-year high for Receivables - Other was $1.1 million in Q2 2023, with the low at $15170.6 in Q2 2025.
The 3-year median for Receivables - Other is $21241.8 (2024), against an average of $231245.4.
The sharpest annual moves came in 2024 and 2025: Receivables - Other slumped 98.29% in 2024, then slipped 17.79% in 2025.
Immuron's Receivables - Other stood at $1.1 million in 2023, then sank by 98.03% to $21241.8 in 2024, then increased by 11.52% to $23688.0 in 2025.
Business Quant data shows IMRN's Receivables - Other at $23688.0 in Q3 2025, $15170.6 in Q2 2025, and $21241.8 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Immuron	6.81 Mn	6.78 Mn	-

Download Data